Free Trial
LON:BVX

BiVictriX Therapeutics (BVX) Share Price, News & Analysis

BiVictriX Therapeutics logo

About BiVictriX Therapeutics Stock (LON:BVX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.54 million shs
Average Volume
108,326 shs
Market Capitalization
£8.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

Receive BVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BVX Stock News Headlines

BiVictrix Therapeutics Share Chat (BVX:JPJ)
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
BiVictriX Therapeutics PLC (BVX)
When Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?
BiVictriX Therapeutics' former chair moves on
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
LON:BVX
CIK
N/A
Phone
N/A
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£2.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-103.99%
Return on Assets
-62.99%

Debt

Debt-to-Equity Ratio
8.81
Current Ratio
4.40
Quick Ratio
7.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
2.20
Book Value
GBX 3 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
82,530,000
Free Float
N/A
Market Cap
£8.25 million
Optionable
Not Optionable
Beta
-0.73
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (LON:BVX) was last updated on 9/10/2024 by MarketBeat.com Staff.
From Our Partners